Olmesartan Medoxomilo Blixie (Olmesartan Medoxomil)

Olmesartan medoxil is used to treat high blood pressure by targeting the renin‑angiotensin system.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Diabetic nephropathy (early stages): slows progression of kidney damage associated with diabetes.
• Heart failure with reduced ejection fraction: used as part of combination therapy to improve outcomes.
• Stroke prevention in high‑risk patients: contributes to lower incidence of recurrent ischemic events.
• Chronic kidney disease (stage 2‑3): assists in blood pressure control to protect renal function.

• Olmesartan medoxil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1, it prevents angiotensin II‑mediated vasoconstriction, aldosterone secretion, and sympathetic activation, leading to vasodilation, reduced sodium and water retention, and ultimately lower arterial pressure.

Olmesartan medoxil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Nasal congestion
• Diarrhea
• Elevated blood potassium (hyperkalaemia)

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension
• Acute kidney injury
• Liver enzyme elevations
• Myocardial infarction in patients with pre‑existing coronary disease
• Severe allergic reactions (anaphylaxis)

When prescribing Olmesartan Medoxomilo Blixie, clinicians should consider several safety aspects.

• Renal function monitoring: assess baseline creatinine and eGFR, repeat as needed.
• Electrolyte balance: check serum potassium, especially in patients on potassium‑sparing diuretics.
• Pregnancy contraindication: avoid use during pregnancy due to fetal toxicity.
• Concomitant NSAID use: monitor for reduced antihypertensive effect and renal impairment.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): risk of renal dysfunction, hyperkalaemia, and hypotension.
• Potassium‑supplement supplements: may cause dangerous hyperkalaemia.
• Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect renal function.
• Diuretics (especially thiazides): may enhance hypotensive effect and alter electrolyte balance.
• ACE inhibitors or other ARBs: additive risk of hypotension, hyperkalaemia, and renal impairment.